Direkt zum Inhalt
Merck
  • Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Journal of clinical epidemiology (2013-07-17)
Jason T Connor, Jordan J Elm, Kristine R Broglio
ZUSAMMENFASSUNG

We present a novel Bayesian adaptive comparative effectiveness trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping. The trial will enroll 720 unique patients in emergency departments and uses a Bayesian adaptive design. The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment. When one treatment is superior to the other two, the trial design provides better patient care, higher power, and a lower expected sample size.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Piracetam
Supelco
Valproinsäure, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-Propylpentansäure
Supelco
Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Phenytoin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Levetiracetam Unreinheit D, European Pharmacopoeia (EP) Reference Standard
Phenytoin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard